Immunohistochemistry Reporting Template

Immunohistochemical studies were performed on formalin-fixed, paraffin-embedded sections of the [INSERT SPECIMEN SOURCE/SITE] specimen in order to [INSERT REASON FOR STAINS]. Stains were performed using antibodies directed against the following antigens: [INSERT], [INSERT], [INSERT], etc. [INSERT CELLS/TISSUE OF INTEREST] are immunoreactive for ____], ____], etc [and fail to stain with the other antibodies tested]. These results support the diagnosis below.

This test was developed and its performance characteristics determined by the University of Michigan Clinical Immunoperoxidase Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. (The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 ["CLIA"] as qualified to perform high complexity testing).

88342 (INSERT # OF ANTIBODIES LISTED IN TEMPLATE ABOVE)

EXAMPLES:
1. single monoclonal antibodies

Immunohistochemical studies were performed on formalin-fixed, paraffin-embedded sections of the lung biopsy specimen in order to more specifically classify this high grade carcinoma. Stains were performed using antibodies directed against the following antigens: cytokeratins (AE1/3, CAM5.2, CK5/6, 34betaE12), p63, thyroid transcription factor-1 (TTF), chromogranin, synaptophysin and CD56. Neoplastic cells are immunoreactive for a subset of cytokeratins (AE1/3 and CAM5.2), TTF, and CD56, and fail to stain with the other antibodies tested. These results support the diagnosis below.

This test was developed and its performance characteristics determined by the University of Michigan Clinical Immunoperoxidase Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. (The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 ["CLIA"] as qualified to perform high complexity testing).

88342 (9)
2. multiple antibody cocktails

Immunohistochemical studies were performed on formalin-fixed, paraffin-embedded sections of the right apex prostate biopsy specimen in order to exclude a diagnosis of adenocarcinoma. Stains were performed using an antibody cocktail comprised of antibodies directed against the following antigens: high molecular weight keratin (34betaE12), p63, and AMACR (p504s). An incomplete basal cell layer is positive for keratin and p63 with negative staining of epithelial cells for AMACR. These results support the diagnosis below.

This test was developed and its performance characteristics determined by the University of Michigan Clinical Immunoperoxidase Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. (The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 ["CLIA"] as qualified to perform high complexity testing).

88342 (3)